Altimumune making headway with Covid-19 programs

Altimmune Inc. is making progress on its Covid-19 vaccine more than four months after jumping that arena. The Gaithersburg biopharma said Monday it has emerged from preclinical trials with positive results, positioning the clinical-stage company to start manufacturing the candidate, called AdCovid, in the third quarter of this year and start a phase 1 clinical trial in the fourth quarter. Specifically, the studies Altimmune (NASDAQ: ALT) ran with the University of Alabama at Birmingham showed…